anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells

BIOLOGICAL2 trials

Sponsors

Barbara Ann Karmanos Cancer Institute

Conditions

LymphomaMultiple Myeloma and Plasma Cell Neoplasm

Phase 1

Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

WithdrawnNCT00521261

Barbara Ann Karmanos Cancer InstituteLymphoma

Start: 2007-10-31End: 2008-07-31Updated: 2014-03-05

Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma

CompletedNCT00938626

Barbara Ann Karmanos Cancer InstituteMultiple Myeloma and Plasma Cell Neoplasm

Start: 2009-10-31End: 2013-03-31Updated: 2013-09-23

Related Papers

The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.

2018-03-076 citations